Global Viral Conjunctivitis Market, By Medication (Lubricating Eye Drops, Vasoconstrictor, Analgesic & Pain Relief, Antiviral, Others), Product Type (Eye Drop, Eye Ointment, Liquid Wipes, Gel, Others), Route of Administration (Oral, Parenteral, Ocular, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Viral Conjunctivitis Market Analysis and Size
The global viral conjunctivitis market is expected to witness significant growth during the forecast period. The rising cases of eye allergy disorders drives the viral conjunctivitis market. The increased viral infection in the eyes due to environmental pollution also boosts the viral conjunctivitis market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global viral conjunctivitis market in the forecast period 2022-2029. The expected CAGR of global viral conjunctivitis market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 300 million in 2021, and it would grow upto USD 443.24 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Conjunctivitis is inflammation in the conjunctiva of the eyes. It is the semi-transparent membrane which protects the white part of the eye and lines the inside of eyelids. Viral conjunctivitis may be caused by the systemic and localised infection. Patients suffering from viral conjunctivitis may show the symptoms of redness and discharge in one or both eyes, watery discharge during the day-mucus rather than pus, burning, sandy, or gritty feeling, a bumpy appearance of the tarsal conjunctiva and severe headache with nausea.
Viral Conjunctivitis Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Medication (Lubricating Eye Drops, Vasoconstrictor, Analgesic & Pain Relief, Antiviral, Others), Product Type (Eye Drop, Eye Ointment, Liquid Wipes, Gel, Others), Route of Administration (Oral, Parenteral, Ocular, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Bausch Health Companies Inc. (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Kubota Vision Inc (U.S.), Alcon Vision LLC (Switzerland), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Novartis AG (Switzerland), Nidek Co Ltd (India), Mitotech, SA (Germany)
Global Viral Conjunctivitis Market Dynamics
- Increase in Conjunctivitis Cases
The increasing number of viral conjunctivitis cases is anticipated to boost the growth of viral conjunctivitis drugs market over the forecast period. As per the National Center for Biotechnology reports, 2017, adenovirus was witnessed as the most common cause of viral conjunctivitis. Around 70 percent of cases of acute conjunctivitis are viral. The number of affected individuals by viral conjunctivitis is projected to rise from 15 to 20 million every year in the U.S. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Increasing R&D Activities and Development
The increased number of research and development activities for improving the effectiveness of viral conjunctivitis drugs is expected to drive the market's growth during the forecast period. For instance, iVIEW Therapeutics Inc., which is a clinical stage ophthalmology drug development company, recently announced the dosing of the first patient in the Phase II clinical trial in 2019. The company is testing the safety and efficacy of the IVIEW-1201 in patients between the age group of more than or equal 15 years for the treatment of acute adenoviral conjunctivitis.
- Increasing Demand for Retail Pharmacies
The rise in the number of viral conjunctivitis therapeutics that is delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Lack of skilled professionals
The lack of healthcare professionals who are unable to treat these patients with appropriate eye lubricants could curb the growth of the global viral conjunctivitis market over a forecast period.
- Risk of Side-Effects
The associated side effects of the application of viral conjunctivitis drugs hampers the market growth. Serious side-effects such as eye pain, change in vision, continued eye redness/irritation and severe side effects such as allergy hampers the market's growth.
This global viral conjunctivitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global viral conjunctivitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Viral Conjunctivitis Market
The COVID-19 pandemic left a great impact on the entire supply chain of the pharmaceutical industry mostly due to strict lockdown in several regions. Also, the demand for conjunctivitis drugs is increasing in this COVID-19 pandemic, due to increasing number of conjunctivitis cases, in which conjunctivitis was the only symptom in COVID-19 positive patients. Thus, this will leave a significant impact on the global viral conjunctivitis market.
Global Viral Conjunctivitis Market Scope
The global viral conjunctivitis market is segmented on the basis of medication, product type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Lubricating Eye Drops
- Analgesic & Pain Relief
- Eye Drop
- Eye Ointment
- Liquid Wipes
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Viral Conjunctivitis Market Regional Analysis/Insights
The global viral conjunctivitis market is analysed and market size insights and trends are provided by medication, product type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global viral conjunctivitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global viral conjunctivitis market throughout the forecasted period due to increased government awareness programs and number of generic drugs.
North America dominates the market due to the presence of key manufacture of the product, high research and development, healthcare expenditure, and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Viral Conjunctivitis Market Share Analysis
The global viral conjunctivitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global viral conjunctivitis market
Key players operating in the global viral conjunctivitis market include:
- Bausch Health Companies Inc. (U.S.)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Kubota Vision Inc (U.S.).
- Alcon Vision LLC (Switzerland)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- Nidek Co Ltd (India)
- Mitotech, SA (Germany)